China's Grandhope Biotech In-licenses Stem Cell Technology From Orthocell

Published: Feb 05, 2013

February 4, 2013 -- Grandhope Biotech of Guangzhou has in-licensed China rights to an autologous stem cell tendon-repair technology from Orthocell Limited of Australia. The technology harvests healthy tendon cells from the patient, cultures them, and then percutaneously implants a mixture of the cells and a scaffolding matrix to the damaged tendon. Terms of the agreement were not disclosed. More details....

Stock Symbol: (SHE: 300238)

Back to news